Advanced Assisted Reproductive Technologies (ART) represent the cutting edge of fertility treatment, offering hope to individuals and couples facing complex reproductive challenges. These innovative methods go beyond conventional IVF to address issues like cancer-related infertility, genetic disease transmission, and ovarian dysfunction. This article will explore key advanced ARTs: In Vitro Maturation (IVM), Ovarian Cryopreservation and Transplantation, and Mitochondrial Donation, detailing their mechanisms, applications, and current effectiveness for students interested in the field.
In Vitro Maturation (IVM): Advancing Oocyte Development
In Vitro Maturation (IVM) is a technique where immature oocytes are collected from the ovaries and matured in a laboratory setting. This approach differs significantly from conventional IVF, which relies on fully mature oocytes retrieved after extensive hormonal stimulation.
What is IVM and How Does It Compare to Conventional ART?
Biologically, IVM involves maturing oocytes from the Germinal Vesicle (GV) stage to Metaphase II (MII) without exposure to hCG or LH. However, clinical definitions have evolved, incorporating variations like minimal FSH stimulation or early hCG administration to prime intermediate follicles, as outlined by the ASRM Committee Opinion. In conventional ART, the natural LH surge or administered hCG triggers nuclear maturation (GVBD to MII) and cytoplasmic maturation, preparing the oocyte for fertilization. IVM seeks to replicate this complex process outside the body.
Oocytes gain the capacity to mature once they are fully grown (over 90uM) and collected from antral follicles, regardless of the menstrual cycle phase. This allows for greater flexibility in collection.
Practical Aspects and Patient Benefits of In Vitro Maturation
The practical application of human IVM involves collecting fully grown GV stage oocytes from 2-12mm antral follicles. This often requires needle modifications (smaller 19-21G needles compared to standard 17G), lowered aspiration pressure (7.5kPa), and filtration of aspirates through 70uM filters. Maturation then typically occurs over a 28-48 hour period.
Compared to conventional Controlled Ovarian Hyperstimulation (COH) for IVF, IVM offers significant patient advantages, as highlighted by Rose et al. (2014):
- Reduced Office Visits: 3-fold less
- Fewer Venipunctures: 4-fold less
- Less Transvaginal Ultrasound Examinations: 2-fold less
- Decreased Endocrine Tests: 11-fold less
- Fewer Self-Injections: Reduced by nearly 50% (none in true IVM)
- Shorter Treatment Period: Interval from starting gonadotropins to hCG reduced by 4.6 days
- Lower Costs: Medication costs reduced by 91%, total cycle cost reduced by 45.9%. This saves the Australian taxpayer $100 million/year in COH costs, and significantly reduces expenses for patients worldwide.
Overall, IVM simplifies and shortens treatment, with less pharmacological intervention, making it a more patient-friendly and cost-effective option.
Who Could Benefit from IVM?
IVM is particularly beneficial for several patient groups:
- High AFC (Antral Follicle Count) Patients: Those at risk of Ovarian Hyperstimulation Syndrome (OHSS), who can mature, fertilize, and either freeze or transfer embryos.
- Low Responders/Older Patients: Can be used in natural cycles to aim for one mature oocyte, with extras for freezing or transfer.
- Cancer Patients: Immature oocytes can be frozen, then thawed and matured later. However, it's not suitable for all cases.
- Oocyte Donors or Females Storing Eggs: A cheaper and less intrusive option for banking immature eggs for future use.
- Poor COH Response: “Rescue IVM” can be considered for immature oocytes retrieved in a conventional IVF cycle.
Progress from Animal Models to Clinical Practice
IVM has shown greater effectiveness in animals, with high maturation rates for murine and bovine oocytes. In bovine IVP (In Vitro Production), developed over 40 years, maturation media, fertilization with frozen-thawed sperm, and blastocyst development rates have been optimized, leading to successful calf births. However, developmental and pregnancy rates in humans have traditionally been lower than in vivo methods, primarily due to inconsistent or non-synchronous cytoplasmic maturation. Efforts to correct this include using phosphodiesterase inhibitors for a two-step IVM process (e.g., CAPA-IVM) and refining techniques.
Epigenetic aberrations, such as Large Animal Syndrome (LOS) seen in IVP-derived animals, are a concern as IVM increases in vitro exposure time.
CAPA-IVM: The Future of IVM?
CAPA-IVM, a technique developed by a UNSW-Belgian team and extensively used in Korea, involves an extended prematuration period with cAMP modulators to enhance oocyte quality. The first Australian clinical use was in 2022, with the first CAPA-IVM baby born in 2023. Approximately 150 CAPA-IVM babies have been born worldwide to date.
CAPA-IVM is offered in specialist centers in Australia for patients at high OHSS risk or needing lower hormone exposure (e.g., PCOS, fertility preservation). Early data suggests outcomes are approaching IVF, but with fewer embryos. Epigenetic alterations are not yet known, but research is ongoing. It is unlikely to fully replace IVF, as the industry still awaits a trusted commercial media and protocol.
"Pseudo IVM" and "Rescue IVM": Variations and Challenges
"Pseudo IVM" is practiced in some clinics, particularly for PCO/PCOS patients. This involves minimal FSH priming (e.g., 100-150IU Gonal F for 3-6 days) followed by hCG trigger. Oocytes are aspirated when the leading follicle is 10-12mm and matured in vitro. Studies by Junk et al. (2012) show promising fertilization and live birth rates (over 40%) in PCO/PCOS patients, with no OHSS cases reported in comparison to IVF cycles (Vu et al. 2019).
"Rescue IVM" refers to maturing immature oocytes collected during a conventional COH cycle that yielded few MII oocytes. These oocytes, often aged and with meiotic/cytoplasmic defects, are cultured in vitro. While some fertilization may occur, development is typically poor due to altered cytoplasmic maturation.
Ovarian Cryopreservation and Transplantation: Preserving Fertility for Cancer Patients
Ovarian cryopreservation offers a vital option for fertility preservation, particularly for women facing cancer treatments that can compromise ovarian function. It involves freezing ovarian tissue for future use.
Techniques and Successes in Ovarian Cryopreservation
Ovarian biopsy and cryopreservation have become standard practices for medical reasons. The slow-freeze method is commonly adopted, though no single standard protocol exists. A common slow-cool technique involves exposing tissue to cryoprotectants like propanediol (PD) and sucrose, followed by controlled cooling. Monash IVF uses 1.5M DMSO + 0.1M sucrose.
More recently, vitrification (a rapid freezing method) has been recommended (e.g., Kitazato method, Silber 2012), which involves sequential exposure to DMSO+EG solutions, then placing tissue on thin metal strips into liquid nitrogen. Vitrification boasts 90% survival rates in vitro, with successful births reported in Japan (Suzuki et al. 2015).
Thawing protocols involve rapid warming followed by decreasing sucrose concentrations. While in vivo transplantation of cryopreserved ovarian slices has resulted in over 150 births worldwide (Silber et al. 2012), it is still considered inefficient. In vitro growth (IVG) of follicles from cryopreserved tissue, followed by oocyte maturation, has been attempted but has not yet led to reported live births.
Innovations in Ovarian Tissue Activation (IVA)
Despite the challenges with IVG, progress is being made. Studies show that culturing cortical strips of the ovary in vitro can support follicle growth. For patients with reduced ovarian reserve (POI/premature ovarian inefficiency), a technique called in vitro activation (IVA) is showing promise. This